Buprenorphine-wafer for drug substitution therapy
US9861628B2 · kind B2 · utility
0Cited by
63References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 22, 2016 |
| Grant date | Jan 9, 2018 |
| Priority date | — |
| Expiry date | Apr 22, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.